CH BEIDAHUANG (00039): Liu Xiaopeng, Zhang Jiahua, Yang Yunguang, and Huang Dexun resign as directors
Noc 00039 of China Beidahuang (00039) issued a notice, that the company received four resignation letters from Mr. Liu Xiaopeng, Mr. Zhang Jiahua, Mr. Yang Yunguang, and Mr. Huang Dexun (collectively referred to as the "relevant individuals") on March 13, 2026.
CH BEIDAHUANG(00039) announces that on March 13, 2026, the company received four resignation letters from Mr. Liu Xiaopeng, Mr. Zhang Jiahua, Mr. Yang Yunguang, and Mr. Huang Dexun (referred to as the "relevant individuals").
On March 13, 2026, the Board of Directors received four resignation letters from the relevant individuals. In the resignation letters, the relevant individuals stated that, for personal reasons and without admitting any liability or compromising their position in litigation, they do not wish to be involved in the company's affairs. If the court determines that the relevant individuals were validly appointed as directors at the board meeting held on June 30, 2025, they confirm their resignation from the director positions.
Given the resignation letters and if the court determines that the relevant individuals were initially validly appointed as directors, the relevant individuals will no longer serve as directors from March 13, 2026 (the date when the company received the resignation letters).
Related Articles

Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.
Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


